Gouty Arthritis Market Report 2026

The gouty arthritis market size has grown strongly in recent years. It will grow from $3.69 billion in 2025 to $3.96 billion in 2026 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to dietary pattern changes, availability of NSAIDs, increased arthritis diagnosis, expansion of rheumatology clinics, pain management drug development.

The gouty arthritis market size is expected to see strong growth in the next few years. It will grow to $5.06 billion in 2030 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to aging population growth, chronic disease awareness, preventive arthritis care, improved patient compliance, personalized gout treatment approaches. Major trends in the forecast period include increasing prevalence of hyperuricemia, rising demand for long-term disease management, growth of combination drug therapies, improved diagnostic imaging adoption, expansion of lifestyle-based disease management.

The rising prevalence of obesity is expected to drive the growth of the gouty arthritis market in the coming years. Obesity is a medical condition characterized by excessive body fat accumulation that poses a risk to an individual’s health and is commonly measured using body mass index (BMI). Increasing rates of obesity are linked to higher consumption of calorie-dense, processed foods and sedentary lifestyles. Obesity contributes to gouty arthritis by raising uric acid production and impairing its excretion, resulting in the buildup of uric acid crystals in the joints. Additionally, excess body weight puts added stress on joints, worsening inflammation and pain associated with the condition. For example, in May 2025, according to the Office for Health Improvement and Disparities, a UK-based government agency, between 2023 and 2024, an estimated 64.5% of adults aged 18 and over in England were overweight or living with obesity, up from 64% in 2022-2023. Therefore, the increasing prevalence of obesity is driving the growth of the gouty arthritis market.

Key companies in the gouty arthritis market are focusing on developing innovative therapies, such as cortrophin gel, to offer more targeted and effective treatment options. Cortrophin gel, also called repository corticotropin injection, is a purified form of adrenocorticotropic hormone (ACTH) used to manage various inflammatory and autoimmune conditions, including gouty arthritis. For instance, in October 2023, ANI Pharmaceuticals, a US-based pharmaceutical company, received FDA approval for a new 1-mL vial of Purified Cortrophin Gel, intended as adjunctive treatment for certain patients experiencing acute gouty arthritis flares. Cortrophin Gel is currently the only FDA-approved ACTH therapy indicated for treating appropriate patients with acute gouty arthritis flares.

In October 2023, Amgen Inc., a US-based biotechnology company, acquired Horizon Therapeutics plc for $27.8 billion. Through this acquisition, Amgen aimed to strengthen and expand its rare-disease and inflammation drug portfolio, broadening its therapeutic offerings and accelerating growth potential. Horizon Therapeutics plc is an Ireland-based biopharmaceutical company specializing in treatments for gouty arthritis.

Major companies operating in the gouty arthritis market are Horizon Therapeutics plc, Pfizer Inc., Takeda Pharmaceutical Company Limited, AbbVie Inc., Bayer AG, Bristol Myers Squibb, Novartis International AG, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., AstraZeneca plc, GlaxoSmithKline plc, Teijin Pharma Ltd, Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, JW Pharmaceutical, Arthrosi Therapeutics Ltd, XORTX Therapeutics Inc, Atom Therapeutics Co Ltd, Olatec Therapeutics LLC, InventisBio Co Ltd, Shanton Pharma, Selecta Biosciences Inc, LG Chem Ltd, Protalix BioTherapeutics Inc.

North America was the largest region in the gouty arthritis market in 2025. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the gouty arthritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the gouty arthritis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are impacting the gouty arthritis market by increasing costs of imported anti-inflammatory drugs, diagnostic imaging equipment, and pharmaceutical ingredients. Hospitals and specialty clinics are most affected due to reliance on imported medications. These tariffs raise treatment costs by increasing expenses for imaging-guided diagnosis and pharmacological management of joint inflammation. However, they support domestic pharmaceutical manufacturing, strengthening regional production of anti-inflammatory therapies.

The gouty arthritis market research report is one of a series of new reports that provides gouty arthritis market statistics, including gouty arthritis industry global market size, regional shares, competitors with a gouty arthritis market share, detailed gouty arthritis market segments, market trends and opportunities, and any further data you may need to thrive in the gouty arthritis industry. This gouty arthritis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Gouty arthritis is a form of inflammatory arthritis marked by sudden, severe episodes of pain, redness, and swelling in the joints, most commonly the big toe. It occurs due to the buildup of uric acid crystals in the joints, causing intense inflammation and discomfort. Gout can be managed through medications and lifestyle modifications to lower uric acid levels and prevent future flare-ups.

The main types of gouty arthritis are acute gouty arthritis and chronic gouty arthritis. Acute gouty arthritis is characterized by sudden onset of intense joint pain, swelling, and redness, often affecting the big toe. Treatments include nonsteroidal anti-inflammatory drugs (NSAIDs), pain relievers, corticosteroids, xanthine oxidase inhibitors, uricosurics, and others. Diagnostic methods include joint fluid analysis, blood tests, X-ray imaging, ultrasound, dual-energy computed tomography (CT) scans, and more. These treatments are distributed through hospital pharmacies, retail pharmacies, and other channels, and are used by end users such as hospitals, specialty clinics, and others.

The gouty arthritis market consists of revenues earned by entities by providing services such as diagnostic testing, physical therapy, pain management programs, and dietary counseling. The market value includes the value of related goods sold by the service provider or included within the service offering. The gouty arthritis market also includes sales of ibuprofen, naproxen, topical pain relievers, and ice packs. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.